The P4Medicine institute's (P4Mi's) mission is to bring P4 Medicine - Predictive, Preventive, Personalized and Participatory - to patients and society.
Board of Directors
Leroy Hood, M.D., Ph.D., Founder and Board Chair
Dr. Hood's outstanding contributions have had a resounding effect on the advancement of science since the 1960s. Throughout his career, he has adhered to the advice of his mentor, Dr. William J. Dreyer: "If you want to practice biology, do it on the leading edge, and if you want to be on the leading edge, invent new tools for deciphering biological information."
Hood was involved in the development of five instruments critical for contemporary biology—namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, and an ink jet printer for constructing DNA arrays. These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine. He helped pioneer the human genome program—making it possible with the automated DNA sequencer. Under Hood's direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15.
In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology, the first of its kind. He has pioneered systems medicine the years since ISB's founding. Hood has made many seminal discoveries in the fields of immunology, neurobiology and biotechnology and, most recently, has been a leader in the development of systems biology, its applications to cancer, neurodegenerative disease, and the linkage of systems biology to personalized medicine.
Hood is now pioneering new approaches to P4 medicine—predictive, preventive, personalized and participatory, and most recently, has embarked on creating a P4 pilot project on 100,000 well individuals, that is transforming healthcare.
In addition to his ground-breaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics and Indi Molecular.
Yiwu He, Ph.D., M.B.A.
Senior program Officer of Discovery and Translation Sciences at the Bill & Melinda Gates Foundation.
Yiwu is responsible for biomarker programs and other drug and vaccine development projects at the Discovery and Translational Sciences at the Gates Foundation. The areas for which he manages the Foundation’s investments include HIV, TB, Pneumonia, Enteric Diarrhea, Polio and other infectious diseases. He also manages multiple R&D programs in China including Next Generation Sequencing partnership with Beijing Genomic Institute, Grant Challenge Exploration with Tsinghua University and HIV/TB drug discovery with Jiao Tong University.
Yiwu is the founder of three US based biotech companies. He also serves as the executive board director of International Society of Vaccine, as well as an adjunct professor at University of Science and Technology of China.
Thomas Brown, M.D., M.B.A.
Thomas Brown, MD, MBA serves as Executive Director of the Swedish Cancer Institute (SCI) overseeing all clinical, research, business, and administrative operations for SCI.
Dr. Brown is responsible for overseeing the Institute’s Swedish-based operations and programs throughout the five hospital campuses, along with network development; leading SCI’s vision in Personalized Medicine initiative, strategy, planning, advocacy and execution work; furthering relationship development with the Providence Health & Services network; organizing and leading efforts to reposition SCI for health-care reform; overseeing the Institute’s clinical research efforts and advanced technology initiatives; as well as championing SCI’s fund-raising efforts. Dr Brown also serves as the Co-Chair of the Cancer Leadership Advisory Council Executive Committee for Providence Health & Services (PHS).
Prior to coming to Swedish, Dr. Brown served as professor of medicine and chief operating officer of the University of Arizona Cancer Center. He served on the faculty of the University of Texas MD Anderson Cancer Center for a decade, to include: as a professor in gastrointestinal oncology; deputy head and head ad interim, of the Division of Cancer Medicine; and vice president for extramural programs and international business. While on the faculty at Duke University, as associate professor of medicine, he led development of the multi-disciplinary GI cancer program and a regional, community-based clinical trial consortium.
He holds a Bachelor of Arts degree from The Johns Hopkins University, and a MBA from Rice University. A graduate of the Medical College of Virginia, Dr. Brown completed an internal medicine residency at the University of Florida and a fellowship in medical oncology at The Johns Hopkins University School of Medicine. Dr. Brown’s clinical practice and research focus has been on therapeutic development in gastrointestinal malignancies. His professional and academic interests include healthcare administration and policy, as well as international healthcare delivery systems.
Dr. Brown has served on numerous institutional, national and international committees and boards; most recently to include The Marsha Rivkin Center for Ovarian Cancer Research, Officer, Board of Directors; Susan G. Komen, Puget Sound Affiliate, Member, Board of Directors; Value in Cancer Care Initiative at the Hutchinson Institute for Cancer Outcomes Research (HICOR), Member, Organizing Committee. Among numerous honors over his career, Dr. Brown was selected as a Jones Scholar while at Rice University and has been selected for inclusion in Best Doctors of America since 1998.
Mauricio Flores, J.D., Executive Director
Mauricio Flores serves as Executive Director of the P4 Medicine institute. He works with P4Mi's Board Chairman, Dr. Leroy Hood to develop a network of integrated P4 Medicine demonstration projects in the United States and globally. Flores is also responsible for engaging other healthcare stakeholders and thought leaders to accelerate the emergence of a P4 Medicine healthcare system that delivers more effective clinical care at lower cost.
A graduate of Harvard Law School, Mr. Flores practiced law for over 30 years with a particular focus on the impact of technological change on society. After clerking for the Chief Justice of the California Supreme Court, he was a partner in two national law firms and the co-founder of a boutique law firm specializing in biomedical intellectual property that integrated scientific and legal expertise in cross-disciplinary teams of lawyers and scientists.
Mr. Flores also has extensive experience in legal, commercial, regulatory and ethics issues impacting medical research institutes, clinical centers, pharmaceutical and medical device companies and healthcare investors. He has tried more than 25 civil cases to a verdict in Federal and California courts as lead counsel and appeared as appellate counsel in numerous state and Federal matters, including a seminal case decided by the United States Supreme Court in June 2005 involving the scope of the Hatch-Waxman Act exemption from patent infringement for FDA-related activities.
Edward Lin, M.D., Medical Director and Chief Medical Officer
Dr. Lin is an associate professor of medicine at the University of Washington, Associate member of Fred Hutchinson Cancer Research Center. He serves as a member of NCCN colorectal cancer guideline committee as well as SWOG GI committee. He also served under UICC Sino-US Hem-Onc visiting scholar program committee. Dr. Lin is a world renowned GI medical oncologist with special interests in colorectal cancer research especially on cancer stem cells and endothelial progenitors. He was elected America’s top physician in 2005 and was voted as the 2014 Cancer Researcher of the Year Award. He pioneered ADAPT treatment and monitoring protocol for advanced colorectal cancer that had dramatically improved patients survival and held 4 patents.
Prior to his appointment at UW, he was an assistant professor of medicine at the University of Texas MD Anderson Cancer Research Center from 2000-2006. Dr. Lin completed his medical school training in 1986 at China Medical University Sum Cum Laud in English Medical Class. He then studied Institute of Basic Medical Science under Professor Pei Hsien Tang, a pioneer in hematopoietic stem cells research in China from 1986-1989. He then studied at the Kenneth Norris Cancer research center and later took a senior research associate position at the Amgen, Inc where he participated in the cloning of thrombopoietin. Dr. Lin completed his internal medicine training at Brown University School of medicine in 1997 and hematology and oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School under Dr. Steven Cannistra.
Dr. Lin had published numerous papers, reviews and book chapters and abstracts. He is the Editor-In-Chief of the popular Cancer-matrix Manual and serves on the editorial board for Stem Cell, Translational Medicine. He is currently the President of the Seattle Chinese Biomedical Association and on the board of Washington Asian Health Professional Association.
Qiang, Tian, M.D., Ph.D., Scientific Director and Chief Science Officer
Qiang Tian, MD, PhD, serves as Scientific Director of the P4 Medicine Institute overseeing scientific and academic affairs of the institute. Dr. Tian is a senior investigator and head of the Cancer & Stem Cell Group at the Institute for Systems Biology. He has also held affiliate and visiting professorships at Chinese Academy of Medical Sciences, Chinese Academy of Sciences, and University of Washington Medical School.
With a career path traversing clinical medicine, molecular genetics, and systems biology, Dr. Tian is primarily interested in applying the powerful systems approach with the enabling genomics, proteomics, and single cell analysis technologies to address some of the most pressing issues pertaining to human health: cancer and stem cell biology, immunity, and disease biomarker discovery. He directs an interdisciplinary team focusing on translational efforts to dissect clonal origin of cancer heterogeneity and the underlying genomic landscape and molecular mechanism contributing to tumorigenesis and therapeutic responses. Dr. Tian has led the development of gene signature panels for cancer patient stratification, and has elucidated protein interaction networks and relevant phosphorylation events in the Wnt signaling pathway. He also contributed to the definition and molecular characterization of several Th cell subsets. He publishes extensively in high impact journals, and is an inventor of three U.S. patents.
Dr. Tian collegially reaches out to global medical communities to promote Systems Medicine and P4 Healthcare. His academic efforts have been continuously supported by federal and foundational grants, including a highly competitive R01 award addressing NCI’s provocative questions. Dr. Tian has served as an expert grant reviewer for funding agencies around the world (US, UK, France, Switzerland, EU, and China), co-founded two US biotech companies, and was Secretary General and President-elect for the Seattle Chinese Biomedical Association.